Please use this identifier to cite or link to this item:
Title: Corticosteroid use in respiratory viral infections — friend or foe?
Authors: Lee, ZY
Tam, JKC 
Tran, T 
Issue Date: 1-Aug-2021
Publisher: Elsevier BV
Citation: Lee, ZY, Tam, JKC, Tran, T (2021-08-01). Corticosteroid use in respiratory viral infections — friend or foe?. Current Opinion in Physiology 22 : 100450-100450. ScholarBank@NUS Repository.
Abstract: Synthetic corticosteroids are among the most widely prescribed anti-inflammatory and immunosuppressive drugs available. In the treatment of respiratory diseases, inhaled corticosteroids, such as dexamethasone and prednisolone, have their indicated uses in the treatment or management of asthma and chronic obstructive pulmonary disease (COPD). However, the molecular mechanisms that underlie corticosteroid's immunoregulatory effects trail well behind its documented clinical efficacy. In support of this, the recent use of corticosteroids to treat inflammation associated with respiratory viral infections, for example, influenza, respiratory syncytial virus, and COVID-19, has emerged as an attractive albeit controversial choice. Here, we provide current opinions on the benefits and risks of using synthetic corticosteroids in respiratory viral infections, which may offer insight into their use to address future respiratory-related health problems.
Source Title: Current Opinion in Physiology
ISSN: 2468-8681
DOI: 10.1016/j.cophys.2021.06.004
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Corticosteroids friend or foe_2021.pdfPublished version449.55 kBAdobe PDF



Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.